Clinical trial
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell…
NCT00091559 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00091559 |
|---|---|
| Title | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) |
| Official title | Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides |
| Intervention type | Drug |
| Interventions | MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months |
| Enrollment | 74 |
| Start date | Feb 3, 2005 |
| Primary completion | Nov 23, 2005 |
| Completion | Mar 13, 2006 |
| First posted | Sep 14, 2004 |
| Last update posted | Apr 5, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: